Cariprazine for the treatment of bipolar depression: a review

References

• Tondo L, Vazquez GH, Baldessarini RJ. Depression and mania in bipolar disorder. Curr Neuropharmacol. 2017 Apr;15(3):353–358. PubMed PMID: 28503106; PubMed Central PMCID: PMC5405618.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Depression. 2018 [cited 2018 Oct 1]. https://www.who.int/en/news-room/fact-sheets/detail/depression/
   Google Scholar
• Evans-Lacko S, Knapp M. Global patterns of workplace productivity for people with depression: absenteeism and presenteeism costs across eight diverse countries. Soc Psychiatry Psychiatr Epidemiol. 2016 Nov;51(11):1525–1537. PubMed PMID: 27667656; PubMed Central PMCID: PMC5101346.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Hirschfeld RM, Frye MA, et al. Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a U.S. community-based sample. J Clin Psychiatry. 2004 Nov;65(11):1499–1504. PubMed PMID: 15554762.
   PubMed Web of Science ®Google Scholar
• Beyer JL. An evidence-based medicine strategy for achieving remission in bipolar disorder. J Clin Psychiatry. 2008;69(Suppl 3): 31–37. PubMed PMID: 18533760.
   PubMed Web of Science ®Google Scholar
• Yatham LN, Goldstein JM, Vieta E, et al. Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry. 2005;66(Suppl 5):40–48. PubMed PMID: 16038601.
   PubMed Web of Science ®Google Scholar
• Ashok AH, Marques TR, Jauhar S, et al. The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment. Mol Psychiatry. 2017 May;22(5):666–679. PubMed PMID: 28289283; PubMed Central PMCID: PMC5401767.
   PubMed Web of Science ®Google Scholar
• Kuroki T, Nagao N, Nakahara T. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Prog Brain Res. 2008;172:199–212. PubMed PMID: 18772034.
   PubMed Web of Science ®Google Scholar
• Dayabandara M, Hanwella R, Ratnatunga S, et al. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat. 2017;13:2231–2241. PubMed PMID: 28883731; PubMed Central PMCID: PMC5574691.
   PubMed Web of Science ®Google Scholar
• Roerig JL, Steffen KJ, Mitchell JE. Atypical antipsychotic-induced weight gain: insights into mechanisms of action. CNS Drugs. 2011 Dec 1;25(12):1035–1059. PubMed PMID: 22133326.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Sanchez R, Jin N, et al. The safety and tolerability of aripiprazole once-monthly as maintenance treatment for bipolar I disorder: A double-blind, placebo-controlled, randomized withdrawal study. J Affect Disord. 2018 Dec 1;241:425–432. PubMed PMID: 30145513.
   PubMed Web of Science ®Google Scholar
• Leggio GM, Salomone S, Bucolo C, et al. Dopamine D(3) receptor as a new pharmacological target for the treatment of depression. Eur J Pharmacol. 2013 Nov 5;719(1–3):25–33. PubMed PMID: 23872400.
   PubMed Web of Science ®Google Scholar
• Lacroix LP, Hows ME, Shah AJ, et al. Selective antagonism at dopamine D3 receptors enhances monoaminergic and cholinergic neurotransmission in the rat anterior cingulate cortex. Neuropsychopharmacol. 2003 May;28(5):839–849. PubMed PMID: 12637956.
   PubMed Web of Science ®Google Scholar
• Strakowski SM, Adler CM, Almeida J, et al. The functional neuroanatomy of bipolar disorder: a consensus model. Bipolar Disord. 2012 Jun;14(4):313–325. PubMed PMID: 22631617; PubMed Central PMCID: PMC3874804.
   PubMed Web of Science ®Google Scholar
• Gyertyan I, Kiss B, Saghy K, et al. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem Int. 2011 Nov;59(6):925–935. PubMed PMID: 21767587.
   PubMed Web of Science ®Google Scholar
• Duric V, Banasr M, Franklin T, et al. Cariprazine exhibits anxiolytic and dopamine d3 receptor-dependent antidepressant effects in the chronic stress model. Int J Neuropsychopharmacology/Official Sci J Collegium Int Neuropsychopharmacologicum. 2017 Oct 1;20(10):788–796. PubMed PMID: 28531264; PubMed Central PMCID: PMC5632312.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Suppes T, Tandon R, et al. Florida best practice psychotherapeutic medication guidelines for adults with major depressive disorder. J Clin Psychiatry. 2017 Jun;78(6):703–713. PubMed PMID: 28682531.
   PubMed Web of Science ®Google Scholar
• Forte A, Baldessarini RJ, Tondo L, et al. Long-term morbidity in bipolar-I, bipolar-II, and unipolar major depressive disorders. J Affect Disord. 2015 Jun 1;178:71–78. PubMed PMID: 25797049.
   PubMed Web of Science ®Google Scholar
• Miller DD. Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry. 2004;6(Suppl 2): 3–7. PubMed PMID: 16001094; PubMed Central PMCID: PMC487011.
   PubMedGoogle Scholar
• Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014 Feb;171(2):160–168. PubMed PMID: 24170180.
   PubMed Web of Science ®Google Scholar
• Samalin L, Garnier M, Pm L. Clinical potential of lurasidone in the management of schizophrenia. Ther Clin Risk Manag. 2011;7:239–250. PubMed PMID: 21753886; PubMed Central PMCID: PMC3132094.
   PubMed Web of Science ®Google Scholar
• Frankel JS, Schwartz TL. Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Ther Adv Psychopharmacol. 2017 Jan;7(1):29–41. PubMed PMID: 28101322; PubMed Central PMCID: PMC5228714.
   PubMed Web of Science ®Google Scholar
• Yatham LN. A clinical review of aripiprazole in bipolar depression and maintenance therapy of bipolar disorder. J Affect Disord. 2011 Jan;128(Suppl 1):S21–8. PubMed PMID: 21220077.
   PubMed Web of Science ®Google Scholar
• Gedeon Richter. European Commission approved Reagila® (cariprazine) for the treatment of schizophrenia 2017 [2018 Oct 1]. Available from https://www.richter.hu/en-US/investors/announcements/Pages/07-19.aspx
   Google Scholar
• Kiss B, Horvath A, Nemethy Z, et al. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010 Apr;333(1):328–340. PubMed PMID: 20093397.
   PubMed Web of Science ®Google Scholar
• Kenakin T. Agonists, partial agonists, antagonists, inverse agonists and agonist/antagonists? Trends Pharmacol Sci. 1987;8(11):423–426.
   Web of Science ®Google Scholar
• Herman A, El Mansari M, Adham N, et al. Involvement of 5-HT1A and 5-HT2A receptors but not α2-adrenoceptors in the acute electrophysiological effects of cariprazine in the rat brain in vivo. Mol Pharmacol. 2018. mol. R118.113290
   PubMed Web of Science ®Google Scholar
• Choi YK, Adham N, Kiss B, et al. Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazine. CNS Spectr. 2017 Dec;22(6):484–494. PubMed PMID: 28059046.
   PubMed Web of Science ®Google Scholar
• Laszlovszky I, N´Emeth G, P´Asztor M´Esz´Aros G, et al. Dopamine D2/D3 receptor occupancy of RGH-188, a D3/D2 antagonist/partial agonist antipsychotic, in healthy volunteers. Eur Neuropsychopharmacol. 2007;17:S455.
   Web of Science ®Google Scholar
• P´Asztor M´Esz´Aros G, Kap´As M, Borsos M, et al. Pharmacokinetics of RGH-188, a new dopamine D3/D2 antagonist/partial agonist atypical antipsychotic, in healthy subjects. Eur Neuropsychopharmacol. 2007;17:S451–S452.
   Web of Science ®Google Scholar
• Center for Drug Evaluation and Research. Applicaiton Number 204370Orig1Orig2s000. Available from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204370Orig1Orig2s000MedR.pdf
   Google Scholar
• Durgam S, Earley W, Lipschitz A, et al. an 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. Am J Psychiatry. 2016 Mar 1;173(3):271–281. PubMed PMID: 26541814. .
   PubMed Web of Science ®Google Scholar
• Clinical Trials. Safety and efficacy of RGH-188 (Cariprazine) in bipolar depression 2018 [cited 2018 Oct 1]. Available from https://clinicaltrials.gov/ct2/show/NCT00852202
   Google Scholar
• Allergan. Allergan announces FDA acceptance of supplemental new drug application for VRAYLAR® (cariprazine) 2018. [cited 2018]. Available from https://www.allergan.com/news/news/thomson-reuters/allergan-announces-fda-acceptance-of-supplemental
   Google Scholar
• De Berardis D, Orsolini L, Iasevoli F, et al. The novel antipsychotic cariprazine (RGH-188): state-of-the-art in the treatment of psychiatric disorders. Curr Pharm Des. 2016;22(33):5144–5162. PubMed PMID: 27396597.
   PubMed Web of Science ®Google Scholar
• Papp M, Gruca P, Lason-Tyburkiewicz M, et al. Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression. Behav Pharmacol. 2014 Sep;25(5–6):567–574. PubMed PMID: 25083572.
   PubMed Web of Science ®Google Scholar
• Neill JC, Grayson B, Kiss B, et al. Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology. Eur Neuropsychopharmacol. 2016 Jan;26(1):3–14. PubMed PMID: 26655189.
   PubMed Web of Science ®Google Scholar
• Nakajima S, Gerretsen P, Takeuchi H, et al. The potential role of dopamine D(3) receptor neurotransmission in cognition. Eur Neuropsychopharmacol. 2013 Aug;23(8):799–813. PubMed PMID: 23791072; PubMed Central PMCID: PMC3748034.
   PubMed Web of Science ®Google Scholar
• Fornaro M, Stubbs B, De Berardis D, et al. Atypical antipsychotics in the treatment of acute bipolar depression with mixed features: a systematic review and exploratory meta-analysis of placebo-controlled clinical trials. Int J Mol Sci. 2016 Feb 16;17(2):241. PubMed PMID: 26891297; PubMed Central PMCID: PMC4783972.
   PubMed Web of Science ®Google Scholar